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OBJECTIVE Type 1 diabetes is accompanied by a significant burden of cardiovascular 
disease (CVD), which is poorly explained by traditional risk factors. We therefore aimed to 
explore whether arterial stiffness estimated by the augmentation index (AIx) predicts mortality 
in individuals with type 1 diabetes. 
 
RESEARCH DESIGN AND METHODS After baseline examination comprising pulse wave 
analysis by applanation tonometry alongside assessment of traditional cardiovascular risk 
factors, 906 individuals with type 1 diabetes from the FinnDiane Study were followed up for a 
median of 8.2 (5.7–9.7) years. Associations between baseline hemodynamics, including AIx, 
and all-cause mortality as well as a composite of cardiovascular and/or diabetes-related 
mortality were investigated using multivariable Cox regression models. 
 
RESULTS The 67 individuals who died during follow-up had higher baseline AIx (28% [21–
33] vs. 19% [9–27], P < 0.001) compared to those alive. This association was independent of 
conventional risk factors (age, sex, BMI, HbA1c, estimated glomerular filtration rate [eGFR] 
and previous CVD event) in Cox regression analysis (standardized hazard ratio 1.71 [1.10–
2.65], P = 0.017) and sustained in a subanalysis of individuals with chronic kidney disease. 
Similarly, higher AIx was associated with the composite secondary endpoint of cardiovascular 
and diabetes-related death (N = 53) after adjustments for sex, BMI, eGFR, previous CVD event 
and height (standardized hazard ratio 2.30 [1.38–3.83], P = 0.001).  
 
CONCLUSIONS AIx predicts all-cause mortality as well as a composite cardiovascular 
and/or diabetes-related cause of death in individuals with type 1 diabetes, independent of 
established cardiovascular risk factors. 
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Cardiovascular disease (CVD) is the leading cause of the excess morbidity and mortality 
observed in individuals with type 1 diabetes, and the standardized mortality ratio is known to 
increase by each stage of diabetic nephropathy (1,2). This predisposition is only partly 
attributable to traditional risk factors, and in fact, cardiovascular risk scores developed for the 
general population and type 2 diabetes are poorly applicable in type 1 diabetes (3). Thus, a 
unique risk factor profile is likely to prevail in these individuals and merits further 
characterization. 
Arterial stiffness is a well-known predictor of mortality in the general population and in 
selected groups, including those with type 2 diabetes, yet no longitudinal studies have been 
carried out in individuals with type 1 diabetes (4,5). Interestingly, arterial stiffening seems to 
occur early in individuals with type 1 diabetes, as their pulse pressure, a crude estimate of 
arterial stiffness, increases up to 15–20 years earlier than in healthy controls (6). This 
phenomenon of early arterial ageing made us hypothesize that arterial stiffness may be an 
important mediating factor leading to premature death in type 1 diabetes. Since 
microangiopathy is a major manifestation of complicated type 1 diabetes, we further 
hypothesized that early signs of arterial stiffening could be detected by the augmentation index 
(AIx), which as a measure of arterial pulse wave reflections is particularly affected by stiffness 
in the small resistance arteries (7). We previously showed that AIx correlates with 
microvascular and macrovascular complications in type 1 diabetes in a cross-sectional setting 
(8). The aim of this study was therefore to explore whether AIx predicts all-cause as well as 
cardiovascular and/or diabetes-related mortality in type 1 diabetes. 
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RESEARCH DESIGN AND METHODS  
The FinnDiane cohort 
This prospective observational follow-up study is part of the ongoing nationwide Finnish 
Diabetic Nephropathy (FinnDiane) Study, in which more than 5400 individuals with type 1 
diabetes have been characterized since 1997. The study protocol has been approved by the local 
ethics committees and written informed consent was obtained from each participant. The 
FinnDiane protocol has been previously described in detail (9). Briefly, baseline data on 
cardiovascular risk factors and diabetic complications are collected from standardized 
questionnaires and medical files, as well as through clinical examination and biochemical 
measurements. Since 2001, noninvasive assessment of arterial stiffness and central 
hemodynamics through pulse wave analysis has been included in the baseline examination of 
those individuals studied at the FinnDiane center in Helsinki.  
Study population 
In this substudy, individuals with available baseline data on arterial stiffness by the year 2015 
were included. Further inclusion criteria were age above 18 years, type 1 diabetes diagnosed 
by the age of 40 and insulin treatment initiated within 1 year of the diagnosis. The baseline 
population comprised 906 individuals (416 men) with a mean age of 43.2 years (standard 
deviation [SD] 12.2), including 134 individuals with chronic kidney disease (CKD), defined as 
an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2, ongoing hemodialysis or 
having received a renal transplant, as well as 98 individuals with a previous CVD event, defined 
as myocardial infarction, coronary revascularization, stroke, lower extremity revascularization 
or non-traumatic amputation. 
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Pulse Wave Analysis 
Applanation tonometry (SphygmoCor, Atcor Medical, Sydney, NSW, Australia) is a 
noninvasive reproducible method to estimate central (aortic) blood pressure variables and 
arterial stiffness through pulse wave analysis (10,11). A high-fidelity micromanometer (SPC-
301; Millar Instruments, Houston, TX) is used to record peripheral pressure waveforms from 
the radial artery of the right arm and three readings with a pattern of at least 20 valid waveforms 
are selected for the analysis. The software generates a central pressure waveform using a 
validated transfer function. This enables determination of central systolic (CSBP) and diastolic 
(CDBP) blood pressure, central pulse pressure (CPP = CSBP − CDBP), central mean arterial 
pressure (CMAP = 1/3 x CSBP + 2/3 x CDBP), central end-systolic pressure (CESP), ejection 
duration (ED), as well as subendocardial viability ratio (SEVR), which indirectly estimates 
myocardial perfusion. To assess stiffness in the small resistance arteries, AIx is calculated as a 
quotient of two measures – the difference of the second and the first systolic peak of the 
pressure waveform (corrected for heart rate) and CPP. 
Clinical endpoints 
Mortality data were obtained from the cause-of-death statistics and the archive of death 
certificates maintained by Statistics Finland. Cardiovascular deaths of individuals with diabetes 
are not uncommonly classified as diabetes-related deaths in Finland, especially in cases where 
no autopsy has been performed. Therefore, we combined cardiovascular and/or diabetes-
related causes of death into one secondary endpoint in the survival analysis, alongside all-cause 
and cardiovascular mortality. 
Statistical methods 
Univariable analyses of established cardiovascular risk factors and hemodynamic variables 
from pulse wave analysis were run to detect differences between those who died during follow-
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up and those who survived. Chi-squared tests were used for dichotomous variables and t-tests 
or Mann–Whitney U tests for continuous variables. Data are presented as mean ± SD (normally 
distributed) or median with interquartile range (non-normally distributed) for continuous 
variables and as percentages for dichotomous variables. 
Longitudinal analysis was performed using Kaplan–Meier survival curves with log-rank tests. 
For multivariable analyses, covariates were standardized by dividing the difference of each 
value and the covariate mean by the standard deviation of that covariate. The best-fit regression 
model for each endpoint was selected using the Akaike information criterion and further 
adjusted for sex and the variable of interest from pulse wave analysis. Independent associations 
with mortality were determined by Cox regression analysis and are presented as standardized 
hazard ratios (sHR) with 95% CI. P values < 0.05 were considered statistically significant. 
 
RESULTS 
Baseline characteristics 
After a median follow-up of 8.2 (5.7–9.7) years, 67 (7.4%) individuals had died (Table 1). 
These individuals were older, had a longer diabetes duration, higher office systolic blood 
pressure, pulse pressure, HbA1c and triglycerides, as well as lower BMI and eGFR at baseline, 
compared to those who survived. Similarly, those who died had more often antihypertensive 
and lipid-lowering medication as well as a previous CVD event at baseline. In the pulse wave 
analysis, AIx (28% [21–33] vs. 19% [9–27]), CSBP (138 [121–150] vs. 119 [109–131] 
mmHg), CMAP (96 [91–105] vs. 91 [85–98] mmHg), CPP (61 [44–80] vs. 41 [34–52] mmHg), 
and CESP (115 [106–125] vs. 105 [96–116] mmHg) were higher, whereas SEVR (116% [102–
138] vs. 142% [123–164]) was lower at baseline in those who died during follow-up.  
 
7 
 
All-cause mortality 
When divided into tertiles based on AIx values, those in the highest tertile showed the highest 
rate of all-cause mortality (Figure 1). Furthermore, AIx was associated with all-cause mortality 
in an unadjusted Cox regression model (Table 2). After adjustments for sex, age, BMI and 
HbA1c, AIx remained in the model with a sHR of 2.14 (1.42–3.23, P < 0.001). In the final 
model, after correcting for two additional strong predictors of mortality, eGFR and previous 
CVD event, AIx was still associated with all-cause mortality (sHR 1.71 [1.10–2.65], P = 
0.017). Similarly, CSBP (sHR 1.29 [1.03–1.62], P = 0.028), CMAP (sHR 1.30 [1.05–1.62], P 
= 0.019) and SEVR (sHR 0.67 [0.47–0.94], P = 0.022) were independently associated with all-
cause mortality in the final model. In a subanalysis including only individuals with CKD, AIx 
showed an even stronger association with all-cause mortality (sHR of 3.39 [1.66–6.91], P = 
0.001), when adjusted for sex, BMI and previous CVD event. 
No adjustments for peripheral blood pressure variables were made in the regression model to 
avoid multicollinearity. AIx correlated with systolic blood pressure (SBP), diastolic blood 
pressure (DBP) and pulse pressure (PP) with Pearson’s correlation coefficients of 0.432, 0.284 
and 0.344, respectively. For comparison with AIx, these variables where added separately to 
the final Cox regression model (sex, age, BMI, HbA1c, eGFR and previous CVD event). 
Independent, yet weaker association with all-cause mortality was seen for SBP (sHR 1.34 
[1.07–1.67], P = 0.011), DBP (sHR 1.28 [1.01–1.63], P = 0.041) and PP (sHR 1.28 [1.00–
1.64], P = 0.046). 
Cardiovascular and diabetes-related mortality 
Of the deaths that occurred during the follow-up, 53 were classified as cardiovascular and/or 
diabetes-related. In an adjusted Cox regression model (Table 3), AIx was independently 
associated with the composite endpoint of cardiovascular and/or diabetes-related mortality 
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(sHR 2.30 [1.38–3.83], P = 0.001). When cardiovascular mortality (N = 36) was analyzed 
separately, AIx was associated with both cardiovascular mortality (sHR 2.36 [1.22–4.53], P = 
0.010) and non-cardiovascular mortality (sHR of 2.11 [1.25–3.56], P = 0.005) in adjusted Cox 
regression analyses. For the other than cardiovascular and/or diabetes-related causes of death 
(N = 14), however, AIx was not a significant risk factor in a Cox regression model adjusted for 
sex (sHR 1.56 [0.82–2.99], P = 0.179). 
 
CONCLUSIONS 
In this study population of 906 individuals with type 1 diabetes followed up for a median of 
8.2 years, AIx was an independent risk factor for all-cause mortality even after adjustments for 
well-known risk factors, including renal function. The same observation was made regarding 
cardiovascular and/or diabetes-related mortality as a composite secondary endpoint, as well as 
in a subanalysis of only individuals with CKD. Other measures of central hemodynamics that 
showed an independent association with all-cause mortality included CSBP, CMAP and 
SEVR. When comparing sHRs, AIx outperformed both the central and the office blood 
pressure variables in predicting all-cause mortality, when separately included in the final 
multivariable model. 
While arterial stiffness indices have been increasingly studied in type 2 diabetes, this is the first 
study to investigate the association between AIx, a surrogate measure of stiffness in the small 
resistance arteries, and mortality in individuals with type 1 diabetes. Earlier studies in type 1 
diabetes have evaluated how the pulse pressure, a crude estimate of stiffness in the large 
arteries, predicts CVD and mortality (12,13). Prospective studies utilizing the gold standard 
measure of arterial stiffness, pulse wave velocity (PWV), are so far limited to type 2 diabetes. 
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Due to different pathophysiological characteristics and the accumulation of CVD at a younger 
age in type 1 diabetes, extrapolating findings from studies of non-diabetic populations or even 
individuals with type 2 diabetes should be made with caution (14). It is of note that in type 1 
diabetes the macrovascular complications may in part have a microvascular origin. In fact, 
small vessel disease is the major underlying cause of ischemic stroke in individuals with type 
1 diabetes, and interestingly, more common compared to individuals with type 2 diabetes (15). 
In the absence of symptomatic CVD, a reduced coronary vascular reactivity has been shown in 
young individuals with type 1 diabetes, and another study demonstrates differences in the 
atherosclerotic morphology of the coronary arteries between the two types of diabetes (16,17). 
Recently, even an autoimmune component has been proposed to play a role in the pathogenesis 
of CVD in type 1 diabetes (18). Although the exact pathogenic mechanisms remain to be 
uncovered, current knowledge implies that type 1 diabetes needs to be considered a separate 
entity when the risks and prevention of cardiovascular complications are studied (14).  
As AIx reflects stiffness in the small resistance arteries, our findings may support the 
hypothesis of small vessel disease contributing to the pathogenesis of macrovascular 
complications and premature mortality seen in type 1 diabetes. The DCCT/EDIC study 
demonstrated the long-standing effects of hyperglycemia on the risk of diabetic complications 
and cardiovascular disease in type 1 diabetes, a phenomenon referred to as “metabolic 
memory” (19). Whether this is partly mediated by small vessel disease and arterial stiffness is 
an open question to be addressed in future research.  
Although noninvasive and applicable for clinical practice, applanation tonometry is operator-
dependent and can be considered time-consuming and costly. However, new operator-
independent technologies to capture central hemodynamics by pulse volume plethysmography 
have been developed in recent years and may improve the feasibility of measuring arterial 
stiffness (20). Indeed, novel clinical risk markers are needed to be able to predict the increased 
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risk of CVD and mortality in type 1 diabetes. Given our findings, AIx could be a useful tool to 
detect such high risk of cardiovascular complications, enabling intensive cardiovascular risk 
control at an early stage for these individuals. Nevertheless, clinical implications require further 
investigation of the added value of AIx in risk prediction models, especially compared to the 
traditional blood pressure variables. This study did show a higher risk of mortality per SD 
increment in AIx as compared to that of SBP, DBP or PP in separate multivariable models. 
The prospective study setting in a large cohort with comprehensive phenotypic data constitutes 
a major strength in our study, whereas its observational design only allows speculations about 
causality. With increasing age, there are some limitations to the reliability of AIx. Following a 
nonlinear pattern, AIx steeply increases in the young while reaching a plateau at older age (21). 
This could partly be explained by the formula itself – concurrent increases in both 
augmentation pressure and CPP could result in AIx remaining stable or even declining (22). 
Central PWV increases later in life, whereas AIx may be preferable in younger populations, 
which is essential when considering the applicability for early detection and prevention of 
CVD. It is not clear, how AIx changes over time in individuals with type 1 diabetes, or whether 
there should be a transfer function specifically validated in type 1 diabetes. However, based on 
the early increase in pulse pressure in type 1 diabetes, one could assume earlier plateauing of 
AIx. Our study population was relatively young, which may have contributed to the predictive 
value of AIx in this study. As PWV measured by applanation tonometry was introduced to the 
FinnDiane protocol at a later stage, complete data powered for prospective analysis are still on 
the way. 
To summarize, AIx as an estimate of stiffness in the small resistance arteries is independently 
associated with all-cause mortality, as well as the composite of cardiovascular and/or diabetes-
related mortality in type 1 diabetes. These results together with our earlier findings suggest that 
detection of early vascular aging in individuals with type 1 diabetes could have complementary 
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value in clinical risk assessment when targeting a more aggressive treatment approach for high-
risk individuals. 
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Table 1. Baseline characteristics according to survival status. 
 Alive Dead P value 
N 839 67  
Male sex (%) 381 (45.4) 35 (52.2) 0.280 
Age (years) 42.5 ± 12.0 52.9 ± 11.4 < 0.001 
Diabetes duration (years) 26.5 ± 12.6 37.4 ± 13.1 < 0.001 
Age at onset (years) 14.0 (9.8–21.9) 13.2 (8.6–21.3) 0.533 
Height (cm) 171.8 ± 9.6 169.5 ± 10.2 0.059 
BMI (kg/m2) 25.1 (22.9–27.6) 23.9 (21.5–26.3) 0.011 
Systolic blood pressure (mmHg) 134 (123–146) 151 (135–166) < 0.001 
Diastolic blood pressure (mmHg) 76 ± 9 77 ± 10 0.632 
Pulse pressure (mmHg) 57 (48–69) 76 (56–93) < 0.001 
Antihypertensive medication (%) 368 (44.1) 53 (79.1) < 0.001 
RAAS-blockers (%) 321 (38.4) 38 (56.7) 0.003 
HbA1c (%) / (mmol/mol) 7.9 (7.2–8.7) / 63 (55–72) 8.3 (7.7–9.3) / 67 (61–78) 0.005 
Total cholesterol (mmol/l) 4.5 (4.0–5.1) 4.6 (4.0–5.3) 0.619 
HDL-cholesterol (mmol/l) 1.53 (1.29–1.86) 1.57 (1.41–2.03) 0.162 
LDL-cholesterol (mmol/l) 2.5 (2.0–3.0) 2.4 (1.9–3.0) 0.337 
Triglycerides (mmol/l) 0.92 (0.70–1.31) 1.10 (0.84–1.55) 0.003 
Statin therapy (%) 213 (25.5) 30 (45.5) < 0.001 
eGFR (ml/min/1.73m2) 103 (87–115) 64 (39–92) < 0.001 
Ever smoked (%) 354 (43.6) 35 (53.8) 0.111 
Previous cardiovascular event* (%) 66 (7.9) 32 (48.5) < 0.001 
Augmentation index (%) 19 (9–27) 28 (21–33) < 0.001 
Subendocardial viability ratio (%) 142 (123–164) 116 (102–138) < 0.001 
Central systolic blood pressure (mmHg) 119 (109–131) 138 (121–150) < 0.001 
Central diastolic blood pressure (mmHg) 77 ± 9 78 ± 10 0.661 
Central mean arterial pressure (mmHg) 91 (85–98) 96 (91–105) < 0.001 
Central pulse pressure (mmHg) 41 (34–52) 61 (44–80) < 0.001 
Ejection duration (ms) 326 ± 22 329 ± 27 0.432 
Central end-systolic pressure (mmHg) 105 (96–116) 115 (106–125) < 0.001 
 
Data presented as N (%), means ± SD or medians (interquartile range). RAAS-blockers = renin-angiotensin-
aldosterone-system blockers, eGFR = estimated glomerular filtration rate (by the Chronic Kidney Disease 
Epidemiology Collaboration [CKD-EPI] formula). *Previous cardiovascular event defined as myocardial 
infarction, coronary revascularization, stroke, lower extremity revascularization or non-traumatic amputation. 
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Table 2. Central hemodynamic variables in association with all-cause mortality in multivariable Cox regression 
models. 
 AIx CSBP CMAP SEVR 
Model 1 
 
2.765 (1.966–3.889) 
P < 0.001 
1.921 (1.601–2.306) 
P < 0.001 
1.608 (1.301–1.988) 
P < 0.001 
0.410 (0.299–0.561) 
P < 0.001 
Model 2 
 
2.565 (1.707–3.854) 
P < 0.001 
1.535 (1.219–1.933) 
P < 0.001 
1.379 (1.099–1.730) 
P = 0.006 
0.493 (0.351–0.691) 
P < 0.001 
Model 3 
 
2.139 (1.418–3.227) 
P < 0.001 
1.467 (1.177–1.828) 
P = 0.001 
1.346 (1.079–1.679) 
P = 0.008 
0.551 (0.390–0.778) 
P = 0.001 
Model 4 
 
1.709 (1.100–2.654) 
P = 0.017 
1.290 (1.029–1.618) 
P = 0.028 
1.301 (1.045–1.621) 
P = 0.019 
0.666 (0.470–0.944) 
P = 0.022 
Data presented as standardized hazard ratios (95% confidence interval) and P values. AIx = augmentation index, 
CSBP = central systolic blood pressure, CMAP = central mean arterial pressure, SEVR = subendocardial 
viability ratio. 
Model 1: unadjusted 
Model 2: age and sex 
Model 3: age, sex, BMI, HbA1c 
Model 4: age, sex, BMI, HbA1c, estimated glomerular filtration rate (eGFR), previous cardiovascular event 
(myocardial infarction, coronary revascularization, stroke, lower extremity revascularization or non-traumatic 
amputation) 
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Table 3. Augmentation index (AIx) in association with cardiovascular and diabetes-related mortality in 
multivariable Cox regression models. 
Cardiovascular/diabetes-related mortality 
yes (N = 53) no (N = 14) 
Added variable AIx sHR (95% CI) Added variable AIx sHR (95% CI) 
 
 
3.469 (2.315–5.199) 
P < 0.001 
 1.426 (0.779–2.609) 
P = 0.250 
+ Male sex  
 
4.402 (2.896–6.691) 
P < 0.001 
+ Male sex 1.561 (0.815–2.991) 
P = 0.179 
+ BMI 4.338 (2.843–6.619) 
P < 0.001 
  
+ eGFR 2.794 (1.767–4.419) 
P < 0.001 
  
+ CVD event  
 
2.743 (1.674–4.493) 
P < 0.001 
  
+ Height  
 
2.296 (1.378–3.825) 
P = 0.001 
  
Cardiovascular mortality 
yes (N = 36) no (N = 31) 
Added variable AIx sHR (95% CI) Added variable AIx sHR (95% CI) 
 3.410 (2.085–5.578) 
P < 0.001 
 2.234 (1.396–3.574) 
P = 0.001 
+ Male sex 4.209 (2.522–7.022) 
P < 0.001 
+ Male sex 2.754 (1.668–4.546) 
P < 0.001 
+ Diabetes duration 2.686 (1.505–4.792) 
P = 0.001 
+ HbA1c 2.514 (1.525–4.143) 
P < 0.001 
+ eGFR 2.157 (1.197–3.887) 
P = 0.010 
+ CVD event 2.213 (1.317–3.716) 
P = 0.003 
+ CVD event 2.355 (1.224–4.530) 
P = 0.010 
+ Total cholesterol 2.105 (1.247–3.555) 
P = 0.005 
AIx = augmentation index, eGFR = estimated glomerular filtration rate (by the Chronic Kidney Disease 
Epidemiology Collaboration [CKD-EPI] formula), CVD event = previous cardiovascular event (myocardial 
infarction, coronary revascularization, stroke, lower extremity revascularization or non-traumatic amputation), 
sHR = standardized hazard ratio, CI = confidence interval. 
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Figure 1. Kaplan–Meier survival curves with log-rank tests for all-cause mortality (N = 67) by augmentation 
index (AIx) tertiles.  
 
